Carouselhttp://www.managingip.com/RSS.aspx?FeedID=2859©2018 Managing Intellectual Property60CarouselThe week in IP – Brexit agreement, Bio-Rad’s $24m damages, new INPI rule, $120m Palm verdict, EPO broccoli patent revocationManaging IP rounds up the latest patent, trade mark and copyright newshttp://www.managingip.com/Article/3844795/The-week-in-IPBrexit-agreement-Bio-Rads-24m-damages-new-INPI-rule-120m-Palm-verdict-EPO-broccoli.htmlSun, 18 Nov 2018 19:15:00 GMTIP Corporate Strategy - A glimpse into the futureSpeakers at the Managing IP Corporate Strategy Summit discussed issues pertinent to in-house counsel, including new ways to exploit IP assets, managing business risk, influencing policy and resolving disputes. Sanjana Kapila reportshttp://www.managingip.com/Article/3844396/IP-Corporate-Strategy-A-glimpse-into-the-future.htmlFri, 16 Nov 2018 10:00:00 GMTUK Supreme Court affirms Warner-Lambert’s pregabalin patent is invalidWarner-Lambert patent was insufficiently disclosed and would not have been infringed by generics even if the claims were valid, in a ruling that raises the bar for plausibility of Swiss form claimshttp://www.managingip.com/Article/3844132/UK-Supreme-Court-affirms-Warner-Lamberts-pregabalin-patent-is-invalid.htmlWed, 14 Nov 2018 20:00:00 GMTPetitioners rushed to PTAB ahead of claim construction changeNovember is already 2018’s record month for Patent Trial and Appeal Board filing, with 178 petitions in the month ahead of November 13’s shift to the Phillips claim construction standardhttp://www.managingip.com/Article/3844118/Petitioners-rushed-to-PTAB-ahead-of-claim-construction-change.htmlWed, 14 Nov 2018 18:00:00 GMTBiosimilar makers forgo “cut-and-thrust” launch tacticsLarge generics drug companies are becoming more diligent and cautious about clearing patent thickets blocking biosimilars than they have traditionally been with small molecule productshttp://www.managingip.com/Article/3843885/Biosimilar-makers-forgo-cut-and-thrust-launch-tactics.htmlWed, 14 Nov 2018 05:00:00 GMT